The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and other areas in myelofibrosis.
|Videos|June 30, 2017
Abemaciclib Shows Activity for HR-Positive Breast Cancer Brain Mets
Author(s)Sara M. Tolaney, MD, MPH
This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor–positive, HER2-negative breast cancer.
Advertisement
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses an early trial studying the CDK4/6 inhibitor abemaciclib for the treatment of brain metastases in patients with hormone receptor (HR)-positive HER2-negative breast cancer.
Tolaney presented the study results (
Advertisement
Related to this article
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.
The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.
Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive non-muscle invasive bladder cancer.
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
3
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
4
The Promise of CERVINO, MajesTEC-3, and EXCALIBER-RRMM in Multiple Myeloma
5